Long-Term Intracranial Outcomes With Combination Dual Immune-Checkpoint Blockade and Stereotactic Radiosurgery in Patients With Melanoma and Non-Small Cell Lung Cancer Brain Metastases

The intracranial benefit of offering dual immune-checkpoint inhibition (D-ICPI) with ipilimumab and nivolumab to patients with melanoma or non-small cell lung cancer (NSCLC) receiving stereotactic radiosurgery (SRS) for brain metastases (BMs) is unknown. We hypothesized that D-ICPI improves local control compared with SRS alone.

Source: International Journal of Radiation Oncology * Biology * Physics - December 11, 2023 Category: Radiology Authors: Eugene J. Vaios, Rachel F. Shenker, Peter G. Hendrickson, Zihan Wan, Donna Niedzwiecki, Sebastian F. Winter, Helen A. Shih, Jorg Dietrich, Chunhao Wang, April K.S. Salama, Jeffrey M. Clarke, Karen Allen, Paul Sperduto, Trey Mullikin, John P. Kirkpatrick, Tags: Clinical Investigation Source Type: research